Sagimet Biosciences (SGMT) Enterprise Value (2023 - 2026)
Sagimet Biosciences' Enterprise Value history spans 5 years, with the latest figure at -$104.5 million for Q1 2026.
- Quarterly Enterprise Value rose 27.69% to -$104.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$104.5 million through Mar 2026, up 27.69% year-over-year, with the annual reading at -$113.1 million for FY2025, 25.21% up from the prior year.
- Enterprise Value came in at -$104.5 million for Q1 2026, up from -$113.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$18.5 million in Q2 2023 to a low of -$193.7 million in Q1 2024.
- The 5-year median for Enterprise Value is -$116.7 million (2025), against an average of -$116.6 million.
- Year-over-year, Enterprise Value tumbled 798.92% in 2024 and then rose 27.69% in 2026.
- Sagimet Biosciences' Enterprise Value stood at -$32.3 million in 2022, then tumbled by 193.39% to -$94.9 million in 2023, then plummeted by 59.38% to -$151.2 million in 2024, then grew by 25.21% to -$113.1 million in 2025, then increased by 7.59% to -$104.5 million in 2026.
- Per Business Quant, the three most recent readings for SGMT's Enterprise Value are -$104.5 million (Q1 2026), -$113.1 million (Q4 2025), and -$116.7 million (Q3 2025).